• Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist.

• Based on these results, the trial has been stopped early.

• The trial included patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis.

• Noting that there were more patients with ulcerated lesions in the placebo arm than in the tilsotolimod arm, topline interim results showed a 70% lower SLN+ rate among patients injected with tilsotolimod as compared to those injected with placebo.

• The placebo SLN+ rate was in the mid-40%s.

• Related: Idera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 Agonist.

• Statistical significance exceeded the pre-specified p-value of 0.008.

• Adverse reactions included injection site reactions, malaise, fever, and flu-like symptoms.

• This interim result validates previously reported results from INTRIM 1 that showed immune activation.

• The trial will continue to relapse-free survival (RFS) and overall survival (OS) at 5 and 10 years after SLN biopsy.

• Price Action: IDRA shares are up 24.50% at $0.44 on the last check Tuesday.

See more from Benzinga

• Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection

• Ampio's Independent Committee Launches Investigation Related To AP-013 Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.